Literature DB >> 21955093

Rosemary and cancer prevention: preclinical perspectives.

Suong N T Ngo1, Desmond B Williams, Richard J Head.   

Abstract

Colorectal cancer is the second leading cause of cancer death in Australia. Nutrition, particularly intake of vegetables and certain plant components, has been reported to have a major role in cancer risk reduction. Recently, there has been a growing research interest in rosemary, a common household plant grown in many parts of the world. This study aims to review scientific evidence from all studies, published from 1996 to March 2010 that examined the protective effects of rosemary on colorectal cancer and other types of cancer. Literature evidence from animal and cell culture studies demonstrates the anticancer potential of rosemary extract, carnosol, carnosic acid, ursolic acid, and rosmarinic acid. No evidence for other rosemary constituents was found. The reported anticancer properties were found to arise through the molecular changes in the multiple-stage process of cancer development, which are dose related and not tissue or species specific. This is evidenced by the ability of rosemary to suppress the development of tumors in several organs including the colon, breast, liver, stomach, as well as melanoma and leukemia cells. The results suggested that the different molecular targets modulated by rosemary and its active constituents are useful indicators of success in clinical cancer chemo-prevention trials.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21955093     DOI: 10.1080/10408398.2010.490883

Source DB:  PubMed          Journal:  Crit Rev Food Sci Nutr        ISSN: 1040-8398            Impact factor:   11.176


  24 in total

Review 1.  The role and place of medicinal plants in the strategies for disease prevention.

Authors:  Abayomi Sofowora; Eyitope Ogunbodede; Adedeji Onayade
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-08-12

2.  Physiological investigations on the effect of olive and rosemary leaves extracts in male rats exposed to thioacetamide.

Authors:  Atef M Al-Attar; Nessreen A Shawush
Journal:  Saudi J Biol Sci       Date:  2014-09-06       Impact factor: 4.219

Review 3.  Plant triterpenoid saponins: biosynthesis, in vitro production, and pharmacological relevance.

Authors:  Tanya Biswas; Upendra N Dwivedi
Journal:  Protoplasma       Date:  2019-07-11       Impact factor: 3.356

4.  The anti-leukemic effect of carnosic acid combined with adriamycin in a K562/A02/SCID leukemia mouse model.

Authors:  Lu-Qun Wang; Ran Wang; Xiang-Xin Li; Xiao-Ning Yu; Xue-Liang Chen; Hao Li
Journal:  Int J Clin Exp Med       Date:  2015-07-15

5.  Carnosol, a dietary diterpene from rosemary (Rosmarinus officinalis) activates Nrf2 leading to sestrin 2 induction in colon cells.

Authors:  Miao Yan; Bhaskar Vemu; Jacob Veenstra; Sakina M Petiwala; Jeremy J Johnson
Journal:  Integr Mol Med       Date:  2018-08-15

6.  Banxia Xiexin decoction, a traditional Chinese medicine, alleviates colon cancer in nude mice.

Authors:  Shuai Yan; Yinzi Yue; Jinbang Wang; Wenting Li; Mingming Sun; Li Zeng; Xiaopeng Wang
Journal:  Ann Transl Med       Date:  2019-08

Review 7.  Carnosol: a phenolic diterpene with cancer chemopreventive potential.

Authors:  Kyung-Soo Chun; Juthika Kundu; In Gyeong Chae; Joydeb Kumar Kundu
Journal:  J Cancer Prev       Date:  2014-06

Review 8.  Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein.

Authors:  Hyun-Jong Cho; In-Soo Yoon
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-06       Impact factor: 2.629

9.  Ursolic acid disturbs ROS homeostasis and regulates survival-associated gene expression to induce apoptosis in intestinal cancer cells.

Authors:  Laxminarayan Rawat; Vijayashree Nayak
Journal:  Toxicol Res (Camb)       Date:  2021-04-12       Impact factor: 3.524

10.  Antioxidant activity of rosemary (Rosmarinus officinalis L.) essential oil and its hepatoprotective potential.

Authors:  Aleksandar Rašković; Isidora Milanović; Nebojša Pavlović; Tatjana Ćebović; Saša Vukmirović; Momir Mikov
Journal:  BMC Complement Altern Med       Date:  2014-07-07       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.